Successful primary medical therapy with somatostatin receptor ligand in acromegaly with thyroid cancer

Shalini Sree Dharan, Nor Azmi Kamaruddin

Research output: Contribution to journalArticle

Abstract

Acromegaly is a rare disease with an annual incidence of 3 to 4 cases in a million.1 Diagnosis is often delayed due to the slow progression of the disease. Persistent elevation of growth hormone (GH) in acromegaly causes a reduction in life expectancy by 10 years. Aside from multiple cardiovascular, respiratory and metabolic co-morbidities, it has also been proven to cause an increased incidence of cancer. The main treatment of acromegaly is surgical excision of the functioning pituitary adenoma. Multiple comorbidities, including obstructive sleep apnea (OSA), left ventricular hypertrophy (LVH) and soft tissue swelling, make surgery complicated, if not impossible. Medical therapy to reduce comorbidities may be indicated in certain situations. Somatostatin receptor ligands (SRL) are able to reduce, and possibly normalize, IGF-1 levels.2 Reduction of insulin-like growth factor-1 (IGF-1), the main mediator of GH, is able to resolve headache, sweating, fatigue and soft tissue swelling, and also reduce ventricular hypertrophy. This case report illustrates the successful use of the SRL octreotide LAR in treating acromegaly. It also confirms the observation from several case series that thyroid cancer is the most common malignancy in acromegaly.

Original languageEnglish
Pages (from-to)169-172
Number of pages4
JournalJournal of the ASEAN Federation of Endocrine Societies
Volume32
Issue number2
DOIs
Publication statusPublished - 1 Nov 2017

Fingerprint

Somatostatin Receptors
Acromegaly
Thyroid Neoplasms
Ligands
Somatomedins
Growth Hormone
Comorbidity
Therapeutics
Sweating
Octreotide
Incidence
Pituitary Neoplasms
Left Ventricular Hypertrophy
Obstructive Sleep Apnea
Rare Diseases
Life Expectancy
Hypertrophy
Fatigue
Headache
Disease Progression

Keywords

  • Acromegaly
  • Octreotide LAR
  • Papillary thyroid cancer
  • Somatostatin receptor ligands

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Successful primary medical therapy with somatostatin receptor ligand in acromegaly with thyroid cancer. / Dharan, Shalini Sree; Kamaruddin, Nor Azmi.

In: Journal of the ASEAN Federation of Endocrine Societies, Vol. 32, No. 2, 01.11.2017, p. 169-172.

Research output: Contribution to journalArticle

@article{49ae8bedcd594b749d484d167a8928ec,
title = "Successful primary medical therapy with somatostatin receptor ligand in acromegaly with thyroid cancer",
abstract = "Acromegaly is a rare disease with an annual incidence of 3 to 4 cases in a million.1 Diagnosis is often delayed due to the slow progression of the disease. Persistent elevation of growth hormone (GH) in acromegaly causes a reduction in life expectancy by 10 years. Aside from multiple cardiovascular, respiratory and metabolic co-morbidities, it has also been proven to cause an increased incidence of cancer. The main treatment of acromegaly is surgical excision of the functioning pituitary adenoma. Multiple comorbidities, including obstructive sleep apnea (OSA), left ventricular hypertrophy (LVH) and soft tissue swelling, make surgery complicated, if not impossible. Medical therapy to reduce comorbidities may be indicated in certain situations. Somatostatin receptor ligands (SRL) are able to reduce, and possibly normalize, IGF-1 levels.2 Reduction of insulin-like growth factor-1 (IGF-1), the main mediator of GH, is able to resolve headache, sweating, fatigue and soft tissue swelling, and also reduce ventricular hypertrophy. This case report illustrates the successful use of the SRL octreotide LAR in treating acromegaly. It also confirms the observation from several case series that thyroid cancer is the most common malignancy in acromegaly.",
keywords = "Acromegaly, Octreotide LAR, Papillary thyroid cancer, Somatostatin receptor ligands",
author = "Dharan, {Shalini Sree} and Kamaruddin, {Nor Azmi}",
year = "2017",
month = "11",
day = "1",
doi = "10.15605/jafes.032.02.12",
language = "English",
volume = "32",
pages = "169--172",
journal = "Journal of the ASEAN Federation of Endocrine Societies",
issn = "0857-1074",
publisher = "ASEAN Federation of Endocrine Societies (AFES)",
number = "2",

}

TY - JOUR

T1 - Successful primary medical therapy with somatostatin receptor ligand in acromegaly with thyroid cancer

AU - Dharan, Shalini Sree

AU - Kamaruddin, Nor Azmi

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Acromegaly is a rare disease with an annual incidence of 3 to 4 cases in a million.1 Diagnosis is often delayed due to the slow progression of the disease. Persistent elevation of growth hormone (GH) in acromegaly causes a reduction in life expectancy by 10 years. Aside from multiple cardiovascular, respiratory and metabolic co-morbidities, it has also been proven to cause an increased incidence of cancer. The main treatment of acromegaly is surgical excision of the functioning pituitary adenoma. Multiple comorbidities, including obstructive sleep apnea (OSA), left ventricular hypertrophy (LVH) and soft tissue swelling, make surgery complicated, if not impossible. Medical therapy to reduce comorbidities may be indicated in certain situations. Somatostatin receptor ligands (SRL) are able to reduce, and possibly normalize, IGF-1 levels.2 Reduction of insulin-like growth factor-1 (IGF-1), the main mediator of GH, is able to resolve headache, sweating, fatigue and soft tissue swelling, and also reduce ventricular hypertrophy. This case report illustrates the successful use of the SRL octreotide LAR in treating acromegaly. It also confirms the observation from several case series that thyroid cancer is the most common malignancy in acromegaly.

AB - Acromegaly is a rare disease with an annual incidence of 3 to 4 cases in a million.1 Diagnosis is often delayed due to the slow progression of the disease. Persistent elevation of growth hormone (GH) in acromegaly causes a reduction in life expectancy by 10 years. Aside from multiple cardiovascular, respiratory and metabolic co-morbidities, it has also been proven to cause an increased incidence of cancer. The main treatment of acromegaly is surgical excision of the functioning pituitary adenoma. Multiple comorbidities, including obstructive sleep apnea (OSA), left ventricular hypertrophy (LVH) and soft tissue swelling, make surgery complicated, if not impossible. Medical therapy to reduce comorbidities may be indicated in certain situations. Somatostatin receptor ligands (SRL) are able to reduce, and possibly normalize, IGF-1 levels.2 Reduction of insulin-like growth factor-1 (IGF-1), the main mediator of GH, is able to resolve headache, sweating, fatigue and soft tissue swelling, and also reduce ventricular hypertrophy. This case report illustrates the successful use of the SRL octreotide LAR in treating acromegaly. It also confirms the observation from several case series that thyroid cancer is the most common malignancy in acromegaly.

KW - Acromegaly

KW - Octreotide LAR

KW - Papillary thyroid cancer

KW - Somatostatin receptor ligands

UR - http://www.scopus.com/inward/record.url?scp=85035783005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035783005&partnerID=8YFLogxK

U2 - 10.15605/jafes.032.02.12

DO - 10.15605/jafes.032.02.12

M3 - Article

VL - 32

SP - 169

EP - 172

JO - Journal of the ASEAN Federation of Endocrine Societies

JF - Journal of the ASEAN Federation of Endocrine Societies

SN - 0857-1074

IS - 2

ER -